Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The study presents two imported malaria cases with a history of travel to malaria-endemic areas and replied late response to treatment. In the blood preparations of the first case, dot-shaped nucleus structures were identified in the erythrocytes, which looked different from the classical erythrocytic forms. In the SD-Pf/Pan test, bands were obtained for both P.f and Pan; while in the SD-Pf/Pv test, a band was obtained for P.f. The 18S rRNA gene was detected using real-time polymerase chain reaction. Artemether-lumefantrine treatment protocol was started. Due to deterioration in general condition on the third day, artemether-lumefantrine treatment was extended to six days, and primaquine phosphate was added. Discharge was on the 16 day of treatment. In the second case, young trophozoites were identified in blood smears. Bands in P.f were obtained in both the SD-Pf/Pan and SD-Pf/Pv tests. Artemether-lumefantrine treatment protocol was started. On the third day of treatment, banana-like gametocytes were observed in blood smears. The patient was discharged at his own request and two days later, upon follow-up, gametocytes were still observed in blood smears. Artemether-lumefantrine treatment was restarted. Gametocytes continued to be observed in the following days. Primaquine phosphate was added to the treatment protocol. The patient was discharged after a 3-week follow-up. The study is presented to draw attention to the increasing cases of imported malaria in Hatay and the increase of malaria cases that respond late to treatment in recent years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4274/tpd.galenos.2024.25633 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Congenital malaria in a neonate born in a malaria-endemic area: a case report.
J Med Case Rep
August 2025
Department of Pediatrics, Dil-Fana Hospital, Arba Minch, Ethiopia.
Background: Malaria remains a significant public health concern, particularly in Africa, where children under 5 years of age are affected. While mosquito bites are the primary transmission route, congenital malaria caused by transplacental or perinatal transmission can also occur. This case report highlights the challenges in diagnosing congenital malaria and emphasizes the importance of considering it in neonates, especially those born in or with a travel history to endemic areas.
View Article and Find Full Text PDFDrug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana.
AIDS Res Ther
August 2025
Medical and Scientific Research Centre, University of Ghana Medical Centre, Legon, Accra, Ghana.
Background: Human Immunodeficiency Virus and malaria are significant public health challenges in sub-Saharan Africa, contributing substantially to morbidity and mortality in the region. The trajectory of HIV and malaria mono- and coinfections may be different with presentations of drug-drug and disease-disease interactions. Current medications of artemether-lumefantrine and dolutegravir (DTG) -based anti-retroviral therapy which are the preferred drugs are metabolised by CYP2B6, CYP3A4/5 and UGTs which are polymorphic and may contribute to drug disposition and clinical outcomes.
View Article and Find Full Text PDFPhysiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether-lumefantrine to supplement the clinical data from the CALINA study.
Trop Med Health
August 2025
Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
Background: Evidence-based recommendations for malaria treatment in patients weighing < 5 kg are lacking as a consequence of differences in pharmacokinetics due to age and/or body weight (BW), and recruitment challenges in conducting trials in this population. A physiologically based pharmacokinetic (PBPK) model was developed and validated to predict artemether and lumefantrine concentrations in patients < 5 kg BW aged 1-28 days. The model predictions supplemented data from a trial (CALINA; NCT04300309) with an optimized dose of artemether-lumefantrine (5 mg artemether: 60 mg lumefantrine) in patients < 5 kg with Plasmodium falciparum malaria.
View Article and Find Full Text PDFEfficacy and gametocyte carriage in Plasmodium falciparum cases treated with artemether-lumefantrine alone versus with single-dose primaquine in Ethiopia: A randomized controlled study.
Acta Trop
August 2025
Department of Biology, Arba Minch University, Arba Minch, Ethiopia. Electronic address:
This study evaluated the efficacy of adding primaquine (PQ) to artemether-lumefantrine (AL) for treating uncomplicated Plasmodium falciparum malaria in Ethiopia. Asexual parasite clearance was monitored with microscopy and molecular techniques, while gametocyte clearance was observed solely through microscopy. Genotyping to distinguish recrudescence from reinfection was performed using nested polymerase chain reaction (PCR).
View Article and Find Full Text PDFEfficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial.
Lancet Infect Dis
August 2025
Infectious Diseases Research Collaboration, Kampala, Uganda; Department of Disease Control and Environmental Health, Makerere University, Kampala, Uganda.
Background: Anti-malarial artemisinin-based combination therapies (ACTs) might be losing efficacy in east Africa, with the spread of artemisinin partial resistance and reduced partner drug activity. Our trial aimed to measure the efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine in three sites in Uganda.
Methods: This randomised, open-label, phase 4 clinical trial was carried out at three sites in the Agago, Arua, and Busia districts of Uganda.